Literature DB >> 6953267

Intracellular adriamycin levels and cytotoxicity in adriamycin-sensitive and adriamycin-resistant P388 mouse leukemia cells.

R Ganapathi, W Reiter, A Krishan.   

Abstract

Adriamycin (ADR) (NSC-123127) uptake and retention in ADR-sensitive P388 leukemia (P388/S) and ADR-resistant P388 leukemia (p388/R) cells were compared by fluorometry and laser flow cytometry (FCM) and were correlated with cytotoxic effects. Drug levels in P388/R cells treated in vitro with ADR (1-10 micrograms/ml) were twofold to fourfold lower than were levels in similarly treated P388/S cells FCM analysis of P388/S and P388/R cells exposed in vitro to ADR showed qualitative and quantitative differences in ADR fluorescence profiles of drug-treated cells (1-5 micrograms/ml) but not of the isolated nuclei (0.5- 10 micrograms/ml). Drug-induced perturbations in cell cycle traverse and chromosome aberrations were seen in P388/S but not in P388/R cells treated with 0.5-5 micrograms ADR/ml in vitro or 4-8 mg ADR/kg in vivo. The role of FCM in rapidly comparing and quantitating cellular ADR fluorescence profiles of ADR-sensitive and ADR-resistant tumors was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6953267

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  11 in total

1.  Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma.

Authors:  N Baldini; K Scotlandi; M Serra; K Kusuzaki; T Shikita; M C Manara; D Maurici; M Campanacci
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  The effects of verapamil and a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-resistant and -sensitive leukemia in vitro and in vivo.

Authors:  S Radel; I Bankusli; E Mayhew; Y M Rustum
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.

Authors:  Olga V Leontieva; Maria N Preobrazhenskaya; Ralph J Bernacki
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

4.  The influence of tumor cell density on cellular accumulation of doxorubicin or cisplatin in vitro.

Authors:  Y Takemura; H Kobayashi; H Miyachi; K Hayashi; S Sekiguchi; T Ohnuma
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Comparison of the cellular pharmacology of doxorubicin in resistant and sensitive models of pancreatic cancer.

Authors:  B K Chang; J A Gregory
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  The mechanism and overcoming of resistance in ACNU-resistant sublines of C6 and 9L rat glioma.

Authors:  T Yoshida; K Shimizu; Y Ushio; T Hayakawa; H Mogami; Y Sakamoto
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

7.  Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion.

Authors:  C Muller; E Chatelut; V Gualano; M De Forni; F Huguet; M Attal; P Canal; G Laurent
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry.

Authors:  R Ganapathi; P Gulick; R Miller; D Grabowski; R Turinic; R Valeunzuela; A Fishleder; R Bukowski
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

9.  Characterization of cellular lipids in doxorubicin-sensitive and -resistant P388 mouse leukemia cells.

Authors:  W M Holleran; M W DeGregorio; R Ganapathi; J R Wilbur; B A Macher
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells.

Authors:  S Radel; W Fredericks; E Mayhew; R Baker
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.